Trials / Conditions / Peripheral T-cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma (PTCL)

11 registered clinical trials studyying Peripheral T-cell Lymphoma (PTCL) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	EARLY_Phase 1
Not Yet Recruiting	A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T NCT06963632	Ruijin Hospital	—
Completed	Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphoc NCT05225584	Kymera Therapeutics, Inc.	Phase 1
Unknown	Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) NCT04696705	Institute of Hematology & Blood Diseases Hospital, China	EARLY_Phase 1
Terminated	Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T- NCT06941688	Seoul National University Hospital	Phase 2
Active Not Recruiting	A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458	Bio-Path Holdings, Inc.	Phase 1
Completed	Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chr NCT02689453	National Cancer Institute (NCI)	Phase 1
Completed	Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT02953652	HUYABIO International, LLC.	Phase 2
Completed	A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) NCT02594267	Acrotech Biopharma Inc.	Phase 1
Terminated	Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cel NCT02314247	Karyopharm Therapeutics Inc	Phase 2
Unknown	A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) NCT00299351	Royal Marsden NHS Foundation Trust	Phase 2